This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, E. A. Articles by Chang, C.-H. Search for Related Content PubMed PubMed Citation Articles by Rossi, E. A. Articles by Chang, C.-H.

Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics

¹ IBC Pharmaceuticals, Inc.; ² Immunomedics, Inc., Morris Plains, New Jersey; and ³ Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey

Requests for reprints: Chien-Hsing Chang, Immunomedics, Inc., 300 American Road, Morris Plains, NJ 07950. Phone: 973-605-1330, ext. 108; Fax: 973-605-1103; E-mail: kchang{at}immunomedics.com or David M. Goldenberg, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109. E-mail: dmg.gscancer{at}att.net.

Key Words: CD20 • Dock-and-Lock • multivalent antibody • veltuzumab • rituximab • non–Hodgkin lymphoma

Multivalent antibodies, either monospecific or bispecific, may improve the efficacy of current therapeutic interventions involving a single monoclonal antibody (mAb). We have applied the Dock-and-Lock (DNL) method, a new platform technology for the site-specific and covalent assembly of modular components into stably tethered complexes of defined composition, to prepare a hexavalent, anti-CD20 antibody, designated Hex-hA20, which comprises six Fabs with one Fc. We show that Hex-hA20 retains the binding activity of all six Fabs, associates with CD20 in lipid rafts, affects antibody-dependent cell-mediated cytotoxicity, but not complement-dependent cytotoxicity, and inhibits proliferation of Daudi, Raji, and Ramos cells in vitro at subnanomolar concentrations without the need for a cross-linking antibody. In addition, Hex-hA20 induces strong homotypical adhesion and is inefficient in stimulating calcium mobilization. Thus, Hex-hA20 exhibits biological properties attributable to both type I and type II anti-CD20 mAbs, as exemplified by rituximab and tositumomab, respectively. Although Hex-hA20 has a short serum half-life, it shows antitumor efficacy in tumor-bearing mice comparable with veltuzumab at equivalent doses. The versatile DNL method was also applied to generate two other multivalent anti-CD20 antibodies without the Fc region, Tri-hA20 and Tetra-hA20, comprising three and four Fabs of veltuzumab, respectively. Similar to Hex-hA20, these were purified to near homogeneity and shown to have potent antiproliferative activity in vitro, thus indicating the need for clustering three or more CD20 molecules on the cell surface to induce growth inhibition. [Cancer Res 2008;68(20):8384–92]

This article has been cited by other articles:

				E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood, October 29, 2009; 114(18): 3864 - 3871. [Abstract] [Full Text] [PDF]

				E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood, June 11, 2009; 113(24): 6161 - 6171. [Abstract] [Full Text] [PDF]